TCGA-BH-A6R9-01A-21R-A32P-07
Mesenchymal profile
This tumor’s EMT hallmark activation ranks 1 of 50 hallmark pathways (GSVA = 0.710). It is a mesenchymal-high tumor — a candidate for EMT-reversal targeting.
Predicted reversal drugs for this tumor
| Drug | Reversal | Adj. score | On-target | Calibrated |
|---|---|---|---|---|
| Palbociclib | -0.122 | -0.163 | 0% | speculative |
| Abemaciclib | -0.159 | -0.204 | 0% | — |
| Encorafenib | -0.152 | -0.209 | 14% | — |
| Rabusertib | -0.178 | -0.239 | 0% | — |
| Asciminib | -0.185 | -0.241 | 0% | — |
| Leniolisib | -0.196 | -0.256 | 0% | — |
| Netarsudil | -0.195 | -0.260 | 0% | — |
| Gedatolisib | -0.199 | -0.260 | 0% | — |
| Capivasertib | -0.204 | -0.269 | 0% | — |
| Darovasertib | -0.203 | -0.276 | 0% | — |
| Ceritinib | -0.217 | -0.284 | 45% | — |
| Defactinib | -0.235 | -0.287 | 0% | — |
| Quizartinib | -0.211 | -0.288 | -73% | ✓ |
| Idelalisib | -0.216 | -0.292 | 0% | speculative |
| Sirolimus | -0.218 | -0.295 | 0% | — |
| Inavolisib | -0.223 | -0.299 | 0% | — |
| Capmatinib | -0.231 | -0.299 | 0% | — |
| Tepotinib | -0.220 | -0.300 | 0% | — |
| Selumetinib | -0.229 | -0.302 | 0% | speculative |
| Cobimetinib | -0.229 | -0.303 | 0% | — |
Measured anti-mesenchymal leaders (Table S9)
Catalog-level reference: the drugs with the strongest S9 expression-weighted coverage of the mesenchymal kinase program, independent of this tumor.
Gilteritinib (49%)Pacritinib (49%)Ponatinib (47%)Midostaurin (45%)Sunitinib (45%)Bosutinib (44%)Nintedanib (43%)Brigatinib (40%)Repotrectinib (38%)Crizotinib (36%)